Immuno-Oncology 2016: onsite registration will be possible
There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society
ESMO’s flagship scientific journal, Annals of Oncology, publishes editorials, reviews, original articles and letters related to oncology
ESMO's new open access, online journal, ESMO Open is open for submission. Learn more about this exciting launch!
Not to miss on Day 5 of the ESMO 2016 Congress in Copenhagen.
28 Oct 2016
FDA also expands the indications for pembrolizumab in second-line treatment to all patients with PD-L1-expressing metastatic NSCLC
27 Oct 2016
It is indicated in newly diagnosed and relapsed/refractory acute promyelocytic leukaemia
26 Oct 2016
Translation provided by Charitable Foundation Research Innovations in Medicine "RIMON". More guides in Russian to follow!
26 Oct 2016
Compendia listings for the tyrosine kinase inhibitor erlotinib
25 Oct 2016
Olaratumab is approved for use with doxorubicin to treat adults with certain types of soft tissue sarcoma
24 Oct 2016
The use is limited to patients whose tumours have specific EGFR mutations
04 Nov - 06 Nov 2016
24 Nov - 27 Nov 2016
16 Dec - 19 Dec 2016
03 Mar - 03 Mar 2017
03 Mar - 05 Mar 2017
16 Mar - 18 Mar 2017